Shares of Atreca (NASDAQ:BCEL) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $25.50 for the company and are anticipating that the company will post ($0.96) EPS for the current quarter, according to Zacks. Zacks has also given Atreca an industry rank of 51 out of 256 based on the ratings given to related companies.
BCEL has been the topic of several recent research reports. Stifel Nicolaus set a $113.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Monday, July 15th. Evercore ISI initiated coverage on shares of Akero Therapeutics in a research report on Monday, July 15th. They set an “outperform” rating and a $35.00 price target on the stock. Cowen restated a “buy” rating on shares of Avrobio in a research report on Monday, July 15th. Finally, Canaccord Genuity initiated coverage on shares of Slack in a research report on Monday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.
Shares of NASDAQ:BCEL opened at $16.01 on Tuesday. Atreca has a fifty-two week low of $14.26 and a fifty-two week high of $20.00.
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Featured Article: Economic Reports
Get a free copy of the Zacks research report on Atreca (BCEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.